. 2020 Jan 7;18:7. doi: 10.1186/s12951-019-0568-x

Table 4.

Separate comparisons of the developed sandwich ELISA-like assay using nanobody-HRP fusion as the detection antibody and direct immunofluorescent assay using nanobody-EGFP fusion with real-time PCR and with a commercial monoclonal antibody-based sandwich ELISA by detecting PPV from the clinical samples

Assay		Number	Real-time PCR		Agreement (%)	Kappa value	Commercial monoclonal antibody-based sandwich ELISA		Agreement (%)	Kappa value
Assay		Number	+	−	Agreement (%)	Kappa value	+	−	Agreement (%)	Kappa value
Developed sandwich ELISA-like assay	+	23	23	0	92.1	0.838	14	9	81.5	0.6
Developed sandwich ELISA-like assay	−	41	5	36	92.1	0.838	2	39	81.5	0.6
Direct immunofluorescent assay	+	17	17	0	81.5	0.635	14	3	90.8	0.796
Direct immunofluorescent assay	−	47	11	36	81.5	0.635	2	45	90.8	0.796

“+” represents positive; “−” as negative